WELLESLEY HILLS, Mass.--(BUSINESS WIRE)--Point Therapeutics, Inc. (NASDAQ: POTP) today announced that the NASDAQ Listing Qualifications Panel (the “Panel”) has granted Point’s request for the continued listing of its securities on The NASDAQ Capital Market. Point’s continued listing is subject to the satisfaction of certain conditions by January 30, 2008, including completion of the previously-announced merger between Point and DARA BioSciences, Inc. (“DARA”) and approval of the NASDAQ initial listing application filed by Point and DARA on October 26, 2007.
